Loading
Created the low, intermediate and high-risk classification that every prostate cancer decision starts from.
Anthony D'Amico developed the 1998 risk stratification of localised prostate cancer by PSA, Gleason score and stage that remains the backbone of guidelines and trial eligibility, and led the randomised trial showing six months of androgen deprivation with radiotherapy improves survival in intermediate and high-risk disease. He continues to publish on PSA kinetics and on tailoring hormone therapy duration.
Shares IMRT / IGRT (modern external beam), Prostate cancer and the tags prostate, radiotherapy.
Shares Androgen deprivation & AR pathway inhibitors, Prostate cancer.
Shares IMRT / IGRT (modern external beam), Prostate cancer and the tags prostate, radiotherapy.
Shares Androgen deprivation & AR pathway inhibitors, Prostate cancer and the tag prostate.
Shares Prostate cancer and the tags prostate, radiotherapy.
Shares Androgen deprivation & AR pathway inhibitors, Prostate cancer and the tag prostate.
Shares Androgen deprivation & AR pathway inhibitors, Prostate cancer.
Shares Prostate cancer and the tags prostate, radiotherapy.